Cost Effectiveness of Tenofovir Disoproxil Fumarate for the Treatment of Chronic Hepatitis B from a Canadian Public Payer Perspective

Author： Dakin Helen   Sherman Morris  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.29, Iss.12, 2011-12, pp. : 1075-1091

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost–Utility Analysis of Tenofovir Disoproxil Fumarate in the Treatment of Chronic Hepatitis B

By Dakin Helen   Bentley Anthony   Dusheiko Geoff  

Value in Health, Vol. 13, Iss. 8, 2010-12 ,pp. : 922-933

Blackwell Publishing

Access to resources Recommend Favorite

Tenofovir Disoproxil Fumarate: In Chronic Hepatitis B

By Perry Caroline M.   Simpson Dene  

Drugs, Vol. 69, Iss. 16, 2009-11 ,pp. : 2245-2256

Adis International

Access to resources Recommend Favorite

Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B

By Kim W. Ray   Loomba Rohit   Berg Thomas   Aguilar Schall Raul E.   Yee Leland J.   Dinh Phillip V.   Flaherty John F.   Martins Eduardo B.   Therneau Terry M.   Jacobson Ira   Fung Scott   Gurel Selim   Buti Maria   Marcellin Patrick  

Cancer, Vol. 121, Iss. 20, 2015-10 ,pp. : 3631-3638

Blackwell Publishing

Access to resources Recommend Favorite

Emtricitabine/Tenofovir Disoproxil Fumarate

By Adis International Limited  

Drugs in R&D, Vol. 5, Iss. 3, 2004-01 ,pp. : 160-161

Adis International

Access to resources Recommend Favorite

Emtricitabine/Tenofovir Disoproxil Fumarate

By Toni M. Dando   Antona J. Wagstaff  

Drugs, Vol. 64, Iss. 18, 2004-01 ,pp. : 2075-2082

Adis International

Access to resources Recommend Favorite